<SEC-DOCUMENT>0001628280-25-015057.txt : 20250327
<SEC-HEADER>0001628280-25-015057.hdr.sgml : 20250327
<ACCEPTANCE-DATETIME>20250327073925
ACCESSION NUMBER:		0001628280-25-015057
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250327
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250327
DATE AS OF CHANGE:		20250327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		25775326

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adc-20250327.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c1d013b0-9589-44ec-aed5-b02f18fac2a5,g:6ff67819-8cd0-44c1-987c-5990e8b71426,d:06fdece82ecf4cefafb96d70e173c8da-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>adc-20250327</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001771910</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="adc-20250327.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-27</xbrli:startDate><xbrli:endDate>2025-03-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i06fdece82ecf4cefafb96d70e173c8da_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="border-top:7pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">CURRENT REPORT<br/>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 27, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ADC Therapeutics SA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Switzerland</ix:nonNumeric></span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39071</ix:nonNumeric></span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification Number)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-6">Biop&#244;le</ix:nonNumeric></span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-7">Route de la Corniche 3B</ix:nonNumeric></span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-8">1066</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Epalinges</ix:nonNumeric></span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-10">Switzerland</ix:nonNumeric></span></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><span><br/></span></div><div style="padding-right:2.75pt"><span><br/></span></div><div style="padding-right:2.75pt"><span><br/></span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">+<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-11">41</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">21 653</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">02 00</ix:nonNumeric></span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Shares, par value CHF 0.08 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">ADCT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. &#167;240.12b-2). Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:7pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div></div><div id="i06fdece82ecf4cefafb96d70e173c8da_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On March 27, 2025, ADC Therapeutics SA (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits.</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20241231pressrelease.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20241231pressrelease.htm">March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20241231pressrelease.htm">27</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20241231pressrelease.htm">, 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20241231pressrelease.htm">025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.460%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADC Therapeutics SA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 27, 2025</span></td><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jose Carmona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jose Carmona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>adct-20241231pressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i995152c3c1fc430cb60aed25c20f372e_1"></div><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">     Exhibit 99.1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">                                                                                    </font><img alt="image_4a.jpg" src="image_4a.jpg" style="height:93px;margin-bottom:5pt;vertical-align:text-bottom;width:166px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:112%">ADC Therapeutics Reports </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA&#174; plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate&#59; data update expected in second quarter 2025</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL&#59; data update anticipated in late 2025 once PFS events reached </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">$250.9M in cash as of December 31, 2024 provides runway expected to fund operations into the second half of 2026</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Company to host conference call today at 8&#58;30 a.m. EDT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">LAUSANNE, Switzerland, March 27, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> -- ADC Therapeutics SA (NYSE&#58; ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8220;We achieved several key milestones in 2024, advancing our expansion trials with ZYNLONTA in combinations and in earlier lines of DLBCL therapy, progressing our early research solid tumor program to the IND-enabling stage and reducing operational spend while at the same time strengthening the balance sheet,&#8221; said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. &#8220;We closed the year by fully enrolling our confirmatory LOTIS-5 DLBCL study, reported encouraging initial data from our LOTIS-7 DLBCL study and were pleased to see promising Phase 2 IIT data reported at the American Society of Hematology annual meeting evaluating ZYNLONTA in indolent lymphomas. We are confident in our path forward and believe we are well positioned for success as we progress toward additional pivotal milestones in 2025.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Fourth Quarter 2024 Operational Updates and Upcoming Milestones</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Full enrollment achieved in LOTIS-5. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Enrollment for the Phase 3 confirmatory trial evaluating ZYNLONTA in combination with rituximab in patients with relapsed or refractory (r&#47;r)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> diffuse large B-cell lymphoma (DLBCL) was completed in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> December 2024. The Company expects to provide updated data before the end of 2025, once the pre-specified number of progression-free survival (PFS) events is reached. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Encouraging initial data from LOTIS-7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> The Company reported positive initial data in December 2024 from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI&#8482;) in patients with r&#47;r non-Hodgkin Lymphoma (NHL). The best overall response rate (ORR) among the 18 r&#47;r DLBCL efficacy evaluable patients was 94%, and the complete response rate (CRR) was 72%. These encouraging efficacy data were observed across patients with different numbers of lines and types of prior treatments. Initial safety data on all 29 r&#47;r NHL patients suggest the combination is generally well tolerated with no dose-limiting toxicities across all dose levels. Enrollment of 40 patients in the dose expansion is expected to be completed in the second quarter of 2025. We expect to share data on a subset of patients in the second quarter of 2025 with a fuller, more mature data update anticipated during the second half of 2025. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Promising data from the Phase 2 investigator-initiated trials evaluating ZYNLONTA in indolent lymphomas</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Updated data from the investigator-initiated trials (IITs) of ZYNLONTA </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">were presented at the 66</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> American Society of Hematology (ASH) Annual Meeting 2024. Both the Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab in patients with r&#47;r follicular lymphoma (FL) and the Phase 2 clinical trial evaluating ZYNLONTA for the treatment of r&#47;r marginal zone lymphoma (MZL) are ongoing and being conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. Results from both trials as presented at ASH and the FL trial simultaneously published in Lancet Haematology can be found </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">here</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Additional data are expected to be shared at a medical conference and&#47;or in publication with plans to engage regulatory agencies and evaluate compendia strategies.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Abstracts to be presented in oral and poster presentations in April at AACR 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. An abstract on the Company&#8217;s Claudin-6 targeting ADC was accepted for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025. Abstracts on the Company&#8217;s PSMA and ASCT2-targeting ADCs were also accepted for poster presentations at the meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Fourth Quarter and Full Year 2024 Financial Results </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Product Revenues&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA reached commercial brand profitability in 2024, generating net product revenues of $16.4 million for the fourth quarter ended December 31, 2024, and $69.3 million for the full year of 2024 as compared to $16.6 million and $69.1 million for the same periods in 2023. The quarter-over-quarter decrease is driven by lower sales volume, partially offset by a higher selling price. The year-to-date increase is primarily attributable to a higher selling price and favorability in prior period GTN sales adjustments, partially offset by lower sales volume.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Research and Development (R&#38;D) Expense&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">R&#38;D expense was $27.1 million and $109.6 million for the fourth quarter and full year ended December 31, 2024, respectively. This compares to R&#38;D expense of $30.3 million and $127.1 million for the same periods in 2023. The decrease during both periods is due primarily to the implementation of productivity initiatives and focused investment in prioritized development programs.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Selling and Marketing (S&#38;M) Expense&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">S&#38;M expense was $11.3 million and $44.0 million for the fourth quarter and full year ended December 31, 2024, respectively. This compares to S&#38;M expense of $13.9 million and $57.5 million for the same periods in 2023. The quarter-over-quarter decrease in S&#38;M expense was primarily due to lower marketing and advertising costs, partially offset by higher share-based compensation expense. The year-to-date decrease was primarily due to lower marketing and advertising costs as well as lower wages and benefits. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">General &#38; Administrative (G&#38;A) Expense&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">G&#38;A expense was $9.6 million and $41.9 million for the fourth quarter and full year ended December 31, 2024, respectively. This compares to G&#38;A expense of $11.3 million and $48.4 million for the same periods in 2023. The quarter-over-quarter decrease in G&#38;A expense was primarily related to lower professional fees. The year-to-date decrease was primarily related to lower share-based compensation expense, professional fees and insurance premiums.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Net Loss&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Net loss for the quarter ended December 31, 2024, was $30.7 million, or a net loss of $0.29 per basic and diluted share, as compared to net loss of $85.0 million, or a net loss of $1.03 per basic and diluted share for the same period in 2023. Net loss for the full year ended December 31, 2024, was $157.8 million, or a net loss of $1.62 per basic and diluted share, as compared to net loss of $240.1 million, or a net loss of $2.94 per basic and diluted share for </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the full year ended December 31, 2023. The decrease in net loss during both periods is primarily attributable to lower income tax expense and lower operating expenses.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Adjusted Net Loss&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Adjusted net loss, which is a non-GAAP financial measure, was $26.5 million, or an adjusted net loss of $0.25 per basic and diluted share for the quarter ended December 31, 2024, as compared to an adjusted net loss of $79.5 million, or $0.97 per basic and diluted share, for the same period in 2023. Adjusted net loss for the full year ended December 31, 2024, was $111.4 million, or an adjusted net loss of $1.15 per basic and diluted share, as compared to net loss of $185.7 million, or an adjusted net loss of $2.27 per basic and diluted share for the full year ended December 31, 2023. The decrease in adjusted net loss during both periods is primarily attributable to lower income tax expense and lower operating expenses. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.03pt">Cash and cash equivalents&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As of December 31, 2024, cash and cash equivalents were $250.9 million, compared to $278.6 million as of December 31, 2023. In May 2024 the Company completed an underwritten offering resulting in net proceeds of approximately $97.4 million, extending the expected cash runway into the second half of 2026.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Conference Call Details</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2024 financial results and provide a company update today at 8&#58;30 a.m. Eastern Time. To access the conference call, please regist</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">er</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">here.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. A live webcast of the call will be available under &#8220;Events &#38; Presentations&#8221; in the Investors section of the ADC Therapeutics website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ir.adctherapeutics.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The archived webcast will be available for 30 days following the call.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:132%">About ZYNLONTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:132%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:132%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA&#174; is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r&#47;r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double&#47;triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.ZYNLONTA.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About ADC Therapeutics</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics (NYSE&#58; ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics&#8217; CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing development.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics is based in Lausanne (Biop&#244;le), Switzerland and has operations in London and New Jersey. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;adctherapeutics.com&#47;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and follow the Company on </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LinkedIn</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA&#174; is a registered trademark of ADC Therapeutics SA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Use of Non-GAAP Financial Measures</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to financial information prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), this document also contains certain non-GAAP financial measures based on management&#8217;s view of performance including&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted total operating expenses</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted net loss</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted net loss per share</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-GAAP measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with GAAP. When preparing these supplemental non-GAAP measures, management typically excludes certain GAAP items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these GAAP items to be normal, recurring cash operating expenses&#59; however, these items may not meet the GAAP definition of unusual or non-recurring items. Since non-GAAP financial measures do not have standardized definitions and meanings, they may differ from the non-GAAP financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other GAAP financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following items are excluded from adjusted total operating expenses&#58;</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Shared-Based Compensation Expense&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following items are excluded from adjusted net loss and adjusted net loss per share&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Shared-Based Compensation Expense&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Certain Other Items&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude certain other significant items that we believe do not represent the performance of our business, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be&#58; changes in the fair value of warrant obligations and the effective interest expense associated with the senior secured term loan facility and the effective interest expense and cumulative catch-up adjustments associated with the deferred royalty obligation under the royalty purchase agreement with HealthCare Royalty Partners.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">See the attached Reconciliation of GAAP Measures to Non-GAAP Measures for explanations of the a</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">mounts excluded and included to arrive at the non-GAAP financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221;, &#8220;seem&#8221;, &#8220;seek&#8221;, &#8220;future&#8221;, &#8220;continue&#8221;, or &#8220;appear&#8221; or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to&#58; the expected cash runway into the second half of 2026&#59; the Company&#8217;s ability to grow ZYNLONTA&#174; revenue in the United States and to expand into combinations, earlier lines of therapy and new indications in the future&#59; the ability of our partners to commercialize ZYNLONTA&#174; in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA&#174; in foreign jurisdictions&#59; the timing, enrollment and results of the Company&#8217;s or its partners&#8217; research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads including the Company&#8217;s exatecan-based platform&#59; the timing, publication, and results of investigator-initiated trials including those studying</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">FL and MZL and the potential regulatory and&#47;or compendia strategy and the future opportunity&#59; the timing and outcome of regulatory submissions for the Company&#8217;s products or product candidates&#59; actions by the FDA or foreign regulatory authorities&#59; projected revenue and expenses&#59; the Company&#8217;s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company&#8217;s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness&#59; and the Company&#8217;s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the &#8220;Risk Factors&#8221; section of the Company's Annual Report on </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.</font></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i995152c3c1fc430cb60aed25c20f372e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except for share and per share data)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Product revenues, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,386&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,643&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,280&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,060&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;License revenues and royalties</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,910</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,790</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,837</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69,558</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,371)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,949)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,529)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,101)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,331)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,633)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,127)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,251)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,927)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,015)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,464)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,623)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,295)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,894)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,424)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,346)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,768)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,491)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,544)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32,436)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39,978)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(130,654)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(165,986)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,272&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,919)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,909)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,211)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,325)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,674&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,457&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,352&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,482)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,433)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,048)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39,872)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(156,136)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(195,419)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,171)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,106)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before equity in net losses of joint venture</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30,727)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(83,043)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(156,302)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(234,525)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in net losses of joint venture</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,544)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,528)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30,727)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(85,031)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(157,846)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(240,053)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.03)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.62)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.94)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,396,677&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,292,594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,159,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,712,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i995152c3c1fc430cb60aed25c20f372e_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,867&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,598&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,316&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,182&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,387&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,177&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,344&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,990&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">307,390</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336,291</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,354&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,511&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest in joint venture</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,980</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">354,782</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,569&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,101&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,469</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,670</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation, long-term</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,093&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,572&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loans</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,632&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,730&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, long-term</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,995&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,879&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524,622</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503,031</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total shareholders&#8217; (deficit) equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(202,642)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(148,249)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and shareholders&#8217; (deficit) equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,980</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">354,782</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i995152c3c1fc430cb60aed25c20f372e_10"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of GAAP Measures to Non-GAAP Measures (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except for share and per share data)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expense</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49,346)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,768)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,422</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(201,491)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(235,544)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,053</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (i)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,495&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46,567)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54,548)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,981</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(193,760)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(222,049)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,289</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">in thousands (except for share and per share data)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30,727)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(85,031)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(157,846)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(240,053)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (i)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,495&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deerfield warrants obligation, change in fair value (income)&#47;expense (ii)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font id="ia46f276632fe4d929d530acf6860a5cf_6-0-1-1-263883"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest expense on senior secured term loan facility (iii)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation interest expense (iv)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,717&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,608&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,915&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation cumulative catch-up adjustment income (iv)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,446)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,823)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,178)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,972)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,480)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79,452)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(111,379)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(185,714)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.03)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.62)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.94)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.25)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.97)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.15)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.27)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,396,677&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,292,594&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,159,966&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,712,166&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i995152c3c1fc430cb60aed25c20f372e_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.65pt">Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted and is recognized over the requisite service period less actual forfeitures by a charge to the statement of operations and a corresponding increase in additional paid-in capital within equity. These accounting entries have no cash impact.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:25.36pt">Change in the fair value of the Deerfield warrant obligation results from the valuation at the end of each accounting period. There are several inputs to these valuations, but those most likely to result in significant changes to the valuations are changes in the value of the underlying instrument (i.e., changes in the price of our common shares) and changes in expected volatility in that price. These accounting entries have no cash impact. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.07pt">Effective interest expense on senior secured term loans relates to the increase in the value of our loans in accordance with the amortized cost method. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.14pt">Deferred royalty obligation interest expense relates to the accretion expense on our deferred royalty obligation pursuant to the royalty purchase agreement with HCR and cumulative catch-up adjustments related to changes in the expected payments to HCR based on a periodic assessment of our underlying revenue projections.</font></div><div style="margin-top:10pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:10pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CONTACTS&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:55.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marcy Graham</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nicole Riley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ADC Therapeutics</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ADC Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marcy.Graham&#64;adctherapeutics.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nicole.Riley&#64;adctherapeutics.com</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">+1 650-667-6450</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">+1 862-926-9040</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:132%">###</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>adc-20250327.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c1d013b0-9589-44ec-aed5-b02f18fac2a5,g:6ff67819-8cd0-44c1-987c-5990e8b71426-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adc="http://adctherapeutics.com/20250327" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://adctherapeutics.com/20250327">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20250327_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20250327_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://adctherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adc-20250327_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c1d013b0-9589-44ec-aed5-b02f18fac2a5,g:6ff67819-8cd0-44c1-987c-5990e8b71426-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b014ec4b-4852-47e7-bc60-7d8019c6eaaf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_32b39d67-23a7-41cd-9602-62667a37c0f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a14ceda0-05ae-45a0-a8f7-63206c3e03d0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d127c7a1-33a6-4f3c-9e15-0cf25f007bf0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_425023ce-03b2-4aea-bdd8-909badfa6664_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_82fbb836-d26b-48e3-96af-02b430699001_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_869dfbf3-18ec-4808-8929-ef07e5cb9347_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_113876f1-11bb-46bc-b48d-ab21f654eb43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_42dfa91d-ebc2-4cf4-afe8-095b2e5ef5fa_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_775bb377-41e5-4edb-8f77-d5e129b22b65_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_44a75e0a-e877-48ed-a22e-727156aa129c_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_769f4001-e3c4-4ea8-83bd-dfa7f439fea3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_40dcf520-32eb-4cef-909f-b3a2447887cb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_ad15c1e1-97b2-4d35-9c95-09fdeb318c53_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bd1f05fb-df87-4559-83f8-ba71ca9019f5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_04db2317-d8d1-4234-8180-5eee7cb6af85_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_04371541-a00f-43d3-8e5c-8e5c8b00c839_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e0140c87-b29e-490f-8ff3-7c48e7a29170_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8c23aef0-c5fa-43ed-b498-c61816bf6e87_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_651e1258-76b2-4b2d-beec-3cd36cf2762c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_1028fe72-9ee9-4b3b-8a45-f97f98872bf3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c09bc445-9d03-4ac8-b4ad-54680dca7b4d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ce2d822a-72ae-4cf0-9b42-ccd8d670e36d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adc-20250327_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c1d013b0-9589-44ec-aed5-b02f18fac2a5,g:6ff67819-8cd0-44c1-987c-5990e8b71426-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://adctherapeutics.com/role/Cover" xlink:type="simple" xlink:href="adc-20250327.xsd#Cover"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1576769f-d4a6-44f9-b725-a29a2424fb41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_DocumentType_1576769f-d4a6-44f9-b725-a29a2424fb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8f6a623a-df76-4134-ab96-73785cb9595b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_DocumentPeriodEndDate_8f6a623a-df76-4134-ab96-73785cb9595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6e2f42f7-e12a-4632-aeb9-7331f7057f95" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityRegistrantName_6e2f42f7-e12a-4632-aeb9-7331f7057f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_eea80a69-6175-4f31-a95c-dde28ffbeafe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_eea80a69-6175-4f31-a95c-dde28ffbeafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1684f065-d8ec-433d-9b1b-5a1b0c95e8e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityFileNumber_1684f065-d8ec-433d-9b1b-5a1b0c95e8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5d4b16b0-e63c-4948-b848-6713e3f6bf65" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityAddressAddressLine1_5d4b16b0-e63c-4948-b848-6713e3f6bf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_dd536371-25df-4f14-b792-28bd97b28321" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityAddressAddressLine2_dd536371-25df-4f14-b792-28bd97b28321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5370a8af-bec1-4a9e-9e12-e4f3508fc84f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityAddressPostalZipCode_5370a8af-bec1-4a9e-9e12-e4f3508fc84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_13958bb4-9451-4ecc-9efe-a6d78ff90ddf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityAddressCityOrTown_13958bb4-9451-4ecc-9efe-a6d78ff90ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_dc4f68ed-df9b-43d1-b151-32f5a398770c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityAddressCountry_dc4f68ed-df9b-43d1-b151-32f5a398770c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_2b900009-fff8-4671-bd4e-e31665d34572" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_CountryRegion_2b900009-fff8-4671-bd4e-e31665d34572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_df38e295-9e57-4de0-b387-c973046a479c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_CityAreaCode_df38e295-9e57-4de0-b387-c973046a479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b8e6b27a-124e-4297-baab-a2068961dbe5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_LocalPhoneNumber_b8e6b27a-124e-4297-baab-a2068961dbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5239d84b-4739-464b-9633-70b79b16c7dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_WrittenCommunications_5239d84b-4739-464b-9633-70b79b16c7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_24791edc-aac6-4dcf-b9ce-0e2020329c47" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_SolicitingMaterial_24791edc-aac6-4dcf-b9ce-0e2020329c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ba3949e3-c166-4d0c-bfe3-7e9a0c600df9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_PreCommencementTenderOffer_ba3949e3-c166-4d0c-bfe3-7e9a0c600df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9bcb3939-0784-4d97-9ee1-11765c35b7eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9bcb3939-0784-4d97-9ee1-11765c35b7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dd06eb86-86e8-4d71-b6de-97b63c02c97b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_Security12bTitle_dd06eb86-86e8-4d71-b6de-97b63c02c97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0b2a7cd5-7800-4ebf-8d43-bcec560fc3db" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_TradingSymbol_0b2a7cd5-7800-4ebf-8d43-bcec560fc3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_db2ac604-974e-43bd-8655-e2ca20d6cfb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_SecurityExchangeName_db2ac604-974e-43bd-8655-e2ca20d6cfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6db5a228-1d2e-4734-809e-0013627c3f60" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityEmergingGrowthCompany_6db5a228-1d2e-4734-809e-0013627c3f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0878b5a5-cf71-46a0-b5c0-6009468f7a33" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_AmendmentFlag_0878b5a5-cf71-46a0-b5c0-6009468f7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_53d7a0ba-35f0-469e-9508-f365d51b176a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d6472f8-6fd7-4f45-b67e-4049c838e4b0" xlink:to="loc_dei_EntityCentralIndexKey_53d7a0ba-35f0-469e-9508-f365d51b176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_4a.jpg
<TEXT>
begin 644 image_4a.jpg
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M> R%\\>=,&!K  !($)>O7B?FHVXF.A0=J7-(1YP<-CEX<@KD1/ASBS6P-0
MQ!Q#ST&4LK,8*N]%Y55'&UOX<XX=L#4  ,00:N@!Q>6BY&*9FPKVQ-O<L#4
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MX4?.6Z6BB66"CC50!6RM!?J[;>>AT_Q!VZ+_&<'6FA")Z6;>BN$W%>SASQ8
MK\#6V4?_;<M<U< IL#60)!+;D7HKAF/S,J 0V#K+-+=UWCIJE>@2?>*V!DZ!
MK8$\T>A>NR^&8U=PH!#8.LN,750BBD2KN*V!4V!K($\DNM=NB^$C=E3PYPF
M#V#K;$)$*%I$JY O$_Q!RP%; U?HW[W^SJ:O127;9'_U1?XD ? !;)TU]%^R
M=>NH51YJX!38&K@B&MUKZ6U2L' +* >VSAK$%J)"M$II11U_T-+ UL M^M^;
M2W[/<,PO \J!K;-#X?:CHC^T2G[1%_Q!NP&V!F[1?^UU3O%?13&;!O/+@')@
MZRR@_Y(M/S5P"FP-/*#_G31%,8OIM[R,/S$ ? -;APVQH.;;EO7Q5P.GP-;
M S,KOA$%J55R%AT0]<P%M[(&00!;ATU^T1>B.;2*SQHX!;8&'M#_QEPYR\I%
M/7-!&1P$ 6P=*J3/*FI#JY!^O\\:. 6V!M[0?*Z9X] URN @(&#K\" 6U'S)
M%LFQ,TW\<7L"M@;>*#K=(CI2JXB&9H,R. @(V#H\<N?M%)VA58AB^8/V"FP-
MO%';?D,4I%:Q'[I&&1P$!&P=$OHOV>H_<1U_T#Z K8%G="^&6Z^ZQJ8H(#A@
MZS#0?]NR/NIJX!38&GBFX,0ET9'ZQ&;#\+R22OYD % $;!T&^B_94E@#I\#6
MP#.:SPS/65\I>IIFV\E&_F0 4 1L'3CZ>TMM#9RB_UG#UCJC^38IHJ=I+E^]
MSI\) (J K8-%_R5;-^<N55L#I\#6P \C#S>*CM0GIA/-L'8+! IL'2#-;9VW
MCEHE>D*K%&X_RA^W"F!KX ?-UW'EO'-0M#4&K4&@P-8!,G91B2@)K1*<L6!K
MX ?=AZ[-=C1;?:R>/PT U %;!\7.0Z=%0VB5FW.7UIQOX8];$; U\(G.0]>F
M.YIAI34(%-@Z$"*Q9"N@&C@%M@8^&5S6(&I2DWQGT]><JF\JV,.?  !*@:T#
M@9A U(-6"=I5L#7PB>ZKKC-M/:"XG#\! )0"6ZM'_VW+ JV!4V!KX)/=#>VB
M(_5)3L'GK*TQQ0P$#6RMF&-GFD0QZ):=AT[SQZT:V!KX1/,-P[E%7)AB!H(&
MME9)<UNG_MN6Y<[;R1]W ,#6P#^B(_4)-RU\?_5%_N@!4 ILK9+\HB]$*VB5
MFW.7*KE]M2.P-?"/SA/-.%OSAPZ :F!K9>B_;5F?4&K@%-@:^"?O2).H24W"
M+N+"A' 0 K"U&DB'5?\E6^'4P"FP-?"/SM/"65MC0C@( =A:#42$H@^T2F@U
M< IL#?RC\[1P=LGUP,U'^$,'0#6PM0*"6+(U\.%7'G]TYI3'I[X^>N+"T<]M
M>V'TWOP1>_-'DK0O&D32L?BACK=(!J?R]L.IO$/R2$?AH]WY \EC)UY[8N_+
M3Y.<^,/SU=L65W]21-)464YRY7PM?R;J@*V!?PY>N"IJ4I\8MIY=>HH_= !4
M UO[Q?^V943,XX=,>WW4LVM^^_3>R4\TS!_4OO W[0L?:"]X,)4W2 :F_O?-
M@=33W;;N577:UE35AJW3JDYER6,=2Q_K6)9+<I7FW2%7BWIS<=68AK7YU1^]
M5?WI\J83Y9>KU2P;A:V!$D1'ZA/8&H0);.T7#TNVGGADQIPGGELS;O27^8^U
M+[BO?<&O4OG]_>V__W7'PE]WJ_KUM*U3JDZ'4W6J8ZU U5>7DPQ-944Z*[O3
MN.:YF@\75'^V@OB[L[69/V<)8&N@!-&1^L18<HWE6R $8&M?2#KI?S]8,#XW
M?]GH9[Z<\DC[_)^WS_]%*K_[9?MK,JH>:*;JM*VIJE.VEE1UKKFJ5V:H^NK*
M8:FL2F?UL,[WAEU<,[9N\YR:_>N;OI:=32-Y9;(8V#H2W+._7M2D)H&M09C
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MV98:YX:M@1*T7G+=LYT9?]  ! !L[86=AT[3%G_00W.6C1Q5.?E7;;/N3&=
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MDEJ<A';$:42M>LM-!7N,YZ2O0JV<D+*V!V!K    7J#]<ODDL'RM$-@:
MT!W8&@   - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8
M&@   - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@
M - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@   - =
MV!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@   - =V!H
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<O[4?V#;E_P?75$V.L?%O6@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 27,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADC Therapeutics SA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">V8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Biop&#244;le<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Route de la Corniche 3B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">1066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Epalinges<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">21 653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">02 00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, par value CHF 0.08 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADCT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001771910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .L\>UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .L\>UHG5!5T[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
M6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<
M_N\-L,+$CN'MB[\!4$L#!!0    ( .L\>UJTY!G;2 0    1   8    >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&ULG9AA;]LV$(;_"J$"Q08DD2@[MI/:!APG
M68*VJ1%[+;9A'VCI;!.51(VDXN3?[RC;4H8J)W=?+)'2O7Y('E^2&FZ5_FXV
M )8]ITEF1M[&VOS2]TVT@528,Y5#AD]62J?"8E&O?9-K$'$9E"9^& 0]/Q4R
M\\;#LFZFQT-5V$1F,-/,%&DJ],L5)&H[\KAWJ'B4ZXUU%?YXF(LUS,'^GL\T
MEOQ*)98I9$:JC&E8C;P)O[P*SUU ^<97"5OSZIZYIBR5^NX*]_'("QP1)!!9
M)R'P\@132!*GA!S_[$6]ZC]=X.O[@_IMV7ALS%(8F*KDFXSM9N0-/!;#2A2)
M?53;.]@WJ 2,5&+*7[;=O=OM>BPJC%7I/A@)4IGMKN)YWQ''!(3[@+#DWOU1
M27DMK!@/M=HR[=Y&-7=3-K6,1CB9N5&96XU/)<;9\50]@1[Z%J5<A1_MPZYV
M8>$;89^%/F-A_X2%07C^WW ?"2J,L,((2[T.A<'^FBR-U3A0?S<1[12ZS0HN
M>R]-+B(8>9B>!O03>./W[W@O^$#P=2J^#J4^OE91@;EHV>(EAR8X.GQP^I&
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MXGIWW-X5K,K+(^Y263PPE[<;$.@8[@5\OE+*'@KNU%Q]]!C_"U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #K/'M:1L=-2)4
M  #-    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( .L\>UHG5!5T[P   "L"   1              "  <,   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .L\>UJ97)PC$ 8  )PG   3
M          "  >$!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MZSQ[6K3D&=M(!    !$  !@              ("!(@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .L\>UJ?H!OPL0(  .(,   -
M          "  : ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ZSQ[6I>*
MNQS     $P(   L              ( !? \  %]R96QS+RYR96QS4$L! A0#
M%     @ ZSQ[6JK$(A8S 0  (@(   \              ( !91   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( .L\>UHD'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( .L\>UIED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adc-20250327.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="adc-20250327.htm">adc-20250327.htm</File>
    <File>adc-20250327.xsd</File>
    <File>adc-20250327_lab.xml</File>
    <File>adc-20250327_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "adc-20250327.htm": {
   "nsprefix": "adc",
   "nsuri": "http://adctherapeutics.com/20250327",
   "dts": {
    "inline": {
     "local": [
      "adc-20250327.htm"
     ]
    },
    "schema": {
     "local": [
      "adc-20250327.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adc-20250327_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adc-20250327_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://adctherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adc-20250327.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adc-20250327.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-25-015057-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-015057-xbrl.zip
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M99VD]4:O7[]=T?YZ;?]?K: S;/=Z/O@%4$L#!!0    ( .L\>UK4'0-^2 H
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MH,Z1@ T)ED03W/TP!EY&PJ0)15I![H?/ P 2R;0>D%KOW#8TTAZUM3=7-[4
ML#.CQ>C"IMY??+V^^/CQC:Y= [O\39,0Q).N?2")#[S3U6<DSG86M@!MOC"P
M,+4%Q7I]H9U\_,_U&PY@_/KF5-<(8&(TH@FJ-, IF!\HJOL@)T*P0Z4.' .5
M4O@=:!ZI=,!H&"!]H@Q 0U4+DOP64?IG?@MR(-5.X.DI/%U@->$:'4A_4"K/
M1"K/09R(1PK%^U=%\0Y0\4Y0\=(H@)L76$P7:Q-\%L CD=2G; 5O$:(J;3>"
MA)9CZH?7/<LRSO\- M4?,A"9 0@!L.E@]=\HZ$06@N8#Z*.0*'8=W"$4P=L
MH*%<@=?#?H5XEX*[E/ HIN)1'P O1 V"##X#L(8,8(D+$@(,I3RB NAEHB-4
M;P%':?D6N!X1F5).VVD<,I!D^0C0QR\E(TV*L'<?KUHT(OT0;Q4$A>],:)"+
M-5?PDXX!M=K]$#:)K,\E(!E1+6/P RP$&MW"9V@4\.^ *@D*C'1(::9SR)GG
M< <LY6($'P'CA2'[IFN7 ,D!>!/4!\J_H]JGP8#YL%O8YSQ7M+4I!OPP3E%
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M2?M_=+RVO?B$,N,OXA^.)L/[7,&#7L 7=\K;B@>9"P_B2>0Q "X.BDRA+>*
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MR\1C^2'*;L!02(K#7F7[&&E4?^0(DX 57A%%*_(/K"Q/$LZIV6.!GMTKCAW
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M,2W=ZEH*.PW%CJ&[SN&/,#P,K;N+KODCJT0P3=TS:W2WJ1J1W75!Z)ZA,--
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M)&-Z"^F#!,JSQ5O6EK07"2/A"CG;JR%FU_\Y"Y3JSV'ID8[)+6WU$TJ^M<@
M@'I&PGLR26?!,6)1JPK(56";E\&K,72 E-2$NW;E:5Y<76HW0YJ0,<U!B:;:
M]45CU_J%^G'D@T?,^YFT>*#]=G'Q6?M 29HGX"-GL89G!<U^>/(U(GG ,AJ<
M-G9C)RS2LF&<PS."5-?H=Y^"M3/ G@MT^;GS/Z;%7P')2/V]U"=#;C--Y20W
MT@ 2(1FG]*SXY;S(?+"([XO?=#XBR2U($BE<W?&"C<;?)[Z>RIBV(>2,#.K(
M-\NOV_RK.8M3?N>V>[WNRJ^-MKGZU@<>VVU;MKW14Q_^SG$VN_.AM?;:MNL>
MR%J]MNEV#F2MAT0#)CS6[AW.8JWNH2RVUP8_\8#6NAY<'PF@/YX\,A>N71)!
M$NJD$7&3FV%"J?8!KANFVILHH(%V17TZZH-JM4U]C=#Y$<+DGH9WZP)E38K9
M2QS16R]%6+6T%O*$RT*UZP:G&HI?R["<9]GF.OF[PX>5K6"U'JPNAR2Z76N\
MJ(+6JU_^J:T-KQ<$%26;E&Q2LFG?T%HJFXYT;KHQ+:Z)RV$$<L#J2GI9HY_T
M*#JN3AQ/MYW.^M5SM39_0-W!QX%-MZ-W.SV%S:/ 9E=W#J*E5A%1@XGHQ+2;
M(PYV:N)L8QC(%DFF,:;2^E5W]3;=3#(YL0Q3=SRS.4RBZ%71ZT/T:KNZZSB*
M7A6]'@*]VHYNN+:R8I45^\0NO^8(O/U9L4?:_L9W>A'\F:?9B$99^L-KM[?
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MM:T*[FMS[EMKJT? E?]E:AW7:'4ZW5;'<8TC84K85:]CM3RKT_(,QUA$6JV
M_:Z_6Q)^]BFZ0+N#HHW^X>O7KQ]+7O#PN4I>E#_[<3"!?X;9*/SE_P-02P$"
M% ,4    " #K/'M:A7GY-&4.  "D70  $               @ $     861C
M+3(P,C4P,S(W+FAT;5!+ 0(4 Q0    ( .L\>UJ,+:*]9 (  /\&   0
M          "  9,.  !A9&,M,C R-3 S,C<N>'-D4$L! A0#%     @ ZSQ[
M6M0= WY("@  '%<  !0              ( !)1$  &%D8RTR,#(U,#,R-U]L
M86(N>&UL4$L! A0#%     @ ZSQ[6DY1P37.!@  M3(  !0
M ( !GQL  &%D8RTR,#(U,#,R-U]P<F4N>&UL4$L! A0#%     @ ZSQ[6N";
ME'+U-@  MLT" !T              ( !GR(  &%D8W0M,C R-#$R,S%P<F5S
B<W)E;&5A<V4N:'1M4$L%!@     %  4 2P$  ,]9      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>adc-20250327_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adc-20250327.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2025-03-27</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001771910</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-03-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ADC Therapeutics SA</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39071</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-6">Biop&#xf4;le</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-7">Route de la Corniche 3B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-8">1066</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Epalinges</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-10">CH</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="c-1" id="f-11">41</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-12">21 653</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">02 00</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Shares, par value CHF 0.08 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">ADCT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
